Success Stories

  1. Develop Clones In Just 9 Weeks From Transfection With Up To 4X Titer 6/15/2026

    Transposon-based cell line development cuts timelines by 10 weeks and hits titers of 4.8 g/L in 17 days. See how SynWeave delivers measurable biologics manufacturing gains.

  2. 3X Bispecific Antibody Output, 98.5% Purity In 7 Months 6/15/2026

    Producing bispecific antibodies at scale is notoriously difficult. See how Syngene achieved a 3X yield increase and 98.5% purity for Hinge Bio's GEM-DIMER™ platform in just seven months.

  3. Direct Scale Up From Clone To 2K GMP Batches 6/15/2026

    N-1 perfusion technology increased antibody titers 1.5–4.5x over conventional fed-batch methods. See how high seed density and media blending cut costs and maximize suite utilization.

  4. Fast-Tracking NDA Approval For A Novel Compound To Treat Infections 6/2/2026

    Strategic tech transfer and scalable manufacturing enabled rapid NDA approval, delivering registration batches and accelerating commercialization of a novel therapy for drug-resistant infections.

  5. Get Up To 4X Titer With N-1 Perfusion 5/26/2026

    N-1 perfusion improves antibody production by increasing cell density, optimizing media and conditions, boosting yields up to 4.5× while maintaining quality and reducing manufacturing time and costs.

  6. Accelerating Development Of A Unique Molecule To Treat Lung Cancer 5/14/2026

    Process development and optimization enabled efficient scale‑up of a complex lung cancer therapy, improving yields, reducing costs, and supporting rapid clinical and commercial progress.

  7. Enabling A Four-Fold Increase In Titer For mAb Manufacturing 5/14/2026

    A platform-based upstream strategy increased monoclonal antibody titers fourfold, improving yield, efficiency, and scalability via optimized clones, process design, and rapid scale-up.

  8. Redefining Cell Line Development For Next-Generation Biologics 4/30/2026

    A transposon‑enabled cell line development strategy streamlines upstream optimization, shortening timelines while improving consistency, yield, and quality across recombinant protein modalities.